Breakthrough Devices To Get Special US Medicare Reimbursement Under CMS Proposal
The US Centers for Medicare and Medicaid Services plans to automatically allow reimbursement and up to 65% new technology add-on payments for US FDA-approved, -cleared or de novo devices in the agency's Breakthrough Devices Program. Industry groups, including the Medical Device Manufacturers Association and AdvaMed, have been pushing CMS for such coverage for several years.
You may also be interested in...
AdvaMed Doubled Its Lobbying Spending Over Past Year
Medtech industry trade group AdvaMed spent more than $2m to help shape US congressional bills in the first quarter of 2020 – more than double what it spent to influence the course of legislation in the first quarter of 2019. Check out our in-depth analysis here.
Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.
AdvaMed Pans CMS Plan To Mandate Publicizing Hospital Rates, But Likes Pay Path For Breakthrough Devices
AdvaMed took issue with several aspects of a US Centers for Medicare and Medicaid Services (CMS) outpatient payment system draft rule mandating that hospitals publicize prices for their surgical procedures and laboratory tests, in comments on the draft. But the medtech industry advocacy group, as well as the Medical Device Manufacturers Association (MDMA), say they support another provision – the agency's new Medicare coverage and payment proposal for breakthrough devices – and requested only minor tweaks to the plan.